BMJ State of the Art (full read) review of ADVANCES in LUPUS THERAPY (Morand EF, et al). - Recent SLE RCTs - Pathogenesis, genetics, epigenetics - Phenotypes - Emerging treatments - Guidelines on Rx https://t.co/OVJRVA8hoz https://t.co/6Srmo5vNjF

Analysis of German RABBIT registry did not show more MACE events in pts w/ JAK inhibitors compared to other DMARDs. 154 MACE w/ 14203 Rx episodes (21218 Pt-Yrs). IRs were 0.68 JAKi, 0.62 TNFi, 0.76 bdMARDs and 0.95 csDMARDs; higher in CV risk pts https://t.co/2UZh4zQFEM https://t.co/VRX2Z8YBrC

FDA has approved another ustekinumab biosimilar (Wezlana) as being interchangeable for use in adults with plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. https://t.co/zbQKjmKgZh https://t.co/UuTDRgCBIV

FDA has approved secukinumab (Cosentyx) for use in adults w/ moderate to severe hidradenitis suppurativa. Recommended dose is 300 mg SC @ wk 0, 1, 2, 3 and 4 and then every 4 weeks thereafter. https://t.co/Pi6RbDbroG https://t.co/AWhbVj2QGa

FDA has approved Abatacept to Treat Juvenile Psoriatic Arthritis (JPsA) in patients aged 2 to 17 years. (JPsA) in patients aged 2 to 17 years. This expands the current indications for ABA use in RA, poly JIA, PsA, and GVHD. https://t.co/eAc8Dsyc3b https://t.co/uHJqhEvuPG

RheumNow Live registration is NOW OPEN! Early bird pricing through 11/30/2023. Register today! https://t.co/1SjBiM7Daj https://t.co/w2cFcj85r5

Choosing steroid sparing therapies in #PMR We have no evidence-based alternative treatment to glucocorticoids in PMR. Few disease-modifying anti-rheumatic drugs, such as methotrexate and leflunomide, are used in daily clinical practice in PMR. https://t.co/zvfAwc7t1z https://t.co/pAJFHF6hOn

Blinkers and the Unseen Information Gap in #PMR https://t.co/uZ9qCPmRw9 https://t.co/lrXRdVGNk2

#PMR Mythbusters: PMR Gets 100% Better Within 72 hours https://t.co/lezwD0J8pL https://t.co/QluGHHnH3X

Why should rheumatologists discuss exercise in #PMR? https://t.co/DBnXetbu2K https://t.co/hfjugw661u

Metanalysis of 26 studies (2252) pts w/ HBsAg-/HBcAb+ RA treated with b/tsDMARDs, shows the pooled HBV reactivation rate was 2.0% HBV reactivation higher w/ RTX (9%), ABA (6%), JAKi (1%); none w/ IL-6i or TNF-i More reactivation if pt is HBsAb- (OR=4.56) https://t.co/fSqvkEGbw3 https://t.co/WGCoZ4nQ3d

FDA Approves Infliximab Biosimilar for Subcutaneous Use Another infliximab biosimilar has been FDA approved, but this new version of Inflectra can be given subcutaneously for patients with inflammatory bowel disease. https://t.co/YnbisOzf0L https://t.co/9AyxEBpasb